Efficacy of ABX196, a new NKT agonist, in prophylactic human vaccination

Vaccine

Volumn 32, Issue 46, 2014, Pages 6138-6145

  Tefit, Josianne Nitcheu ^a   Crabé, Sandrine ^a   Orlandini, Bernard ^b   Nell, Haylene ^c   Bendelac, Albert ^d   Deng, Shenglou ^e   Savage, Paul B ^e   Teyton, Luc ^f   Serra, Vincent ^a  

^a Abivax   (France)

^b Phinc   (France)

^c Karl Bremer Hospital   (South Africa)

^d UNIVERSITY OF CHICAGO   (United States)

^e Brigham Young University   (United States)

^f SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

ABX196; Adjuvant; Glycolipid; NKT cells; GalCer

Indexed keywords

ABX 196; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; GAMMA INTERFERON; GLYCOLIPID; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; IMMUNOLOGICAL ADJUVANT; RECOMBINANT HEPATITIS B VACCINE; UNCLASSIFIED DRUG; ABX196; ALPHA-GALACTOSYLCERAMIDE; GALACTOSYLCERAMIDE; HEPATITIS B ANTIBODY; IFNG PROTEIN, HUMAN;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIBODY RESPONSE; ANTIBODY TITER; ANTIGEN SPECIFICITY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASTHENIA; CELL ACTIVATION; COHORT ANALYSIS; CONTROLLED STUDY; CYTOKINE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; HEADACHE; HEPATITIS B; HIGH RISK POPULATION; HUMAN; IMMUNOGENICITY; INFECTION PREVENTION; LIVER TOXICITY; MALE; NATURAL KILLER T CELL; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; VACCINATION; ANIMAL; BLOOD; CHEMICAL STRUCTURE; CHEMISTRY; CLINICAL TRIAL; IMMUNOLOGY; MACACA FASCICULARIS; MOUSE;

ADJUVANTS, IMMUNOLOGIC; ADULT; ANIMALS; DOUBLE-BLIND METHOD; GALACTOSYLCERAMIDES; HEPATITIS B; HEPATITIS B ANTIBODIES; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VACCINES; HUMANS; INTERFERON-GAMMA; MACACA FASCICULARIS; MALE; MICE; MOLECULAR STRUCTURE; NATURAL KILLER T-CELLS;

EID: 84907996747     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2014.08.070     Document Type: Article

References (20)

1. Brennan P.J., Tatituri R.V., Brigl M., Kim E.Y., Tuli A., Sanderson J.P., et al. Invariant natural killer T cells recognize lipid self antigen induced by microbial danger signals. Nat Immunol 2011, 12:1202-1211.
2. Freigang S., Landais E., Zadorozhny V., Kain L., Yoshida K., Liu Y., et al. Scavenger receptors target glycolipids for natural killer T cell activation. J Clin Investig 2012, 122:3943-3954.
3. Lawson V. Turned on by danger: activation of CD1d-restricted invariant natural killer T cells. Immunology 2012, 137:20-27.
4. Liu Y., Goff R.D., Zhou D., Mattner J., Sullivan B.A., Khurana A., et al. A modified alpha-galactosyl ceramide for staining and stimulating natural killer T cells. J Immunol Methods 2006, 312:34-39.
5. Zhou X.T., Forestier C., Goff R.D., Li C., Teyton L., Bendelac A., et al. Synthesis and NKT cell stimulating properties of fluorophore- and biotin-appended 6"-amino-6"-deoxy-galactosylceramides. Organ Lett 2002, 4:1267-1270.
6. Kim S., Lalani S., Parekh V.V., Wu L., Van Kaer L. Glycolipid ligands of invariant natural killer T cells as vaccine adjuvants. Expert Rev Vaccines 2008, 7:1519-1532.
7. Takeda K., Hayakawa Y., Van Kaer L., Matsuda H., Yagita H., Okumura K. Critical contribution of liver natural killer T cells to a murine model of hepatitis. Proc Natl Acad Sci USA 2000, 97:5498-5503.
8. Wilson M.T., Johansson C., Olivares-Villagomez D., Singh A.K., Stanic A.K., Wang C.R., et al. The response of natural killer T cells to glycolipid antigens is characterized by surface receptor down-modulation and expansion. Proc Natl Acad Sci USA 2003, 100:10913-10918.
9. Parekh V.V., Wilson M.T., Olivares-Villagomez D., Singh A.K., Wu L., Wang C.R., et al. Glycolipid antigen induces long-term natural killer T cell anergy in mice. J Clin Investig 2005, 115:2572-2583.
10. Giaccone G., Punt C.J., Ando Y., Ruijter R., Nishi N., Peters M., et al. A phase I study of the natural killer T-cell ligand alpha-galactosylceramide (KRN7000) in patients with solid tumors. Clin Cancer Res 2002, 8:3702-3709.
11. Chang D.H., Osman K., Connolly J., Kukreja A., Krasovsky J., Pack M., et al. Sustained expansion of NKT cells and antigen-specific T cells after injection of alpha-galactosyl-ceramide loaded mature dendritic cells in cancer patients. J Exp Med 2005, 201:1503-1517.
12. Ishikawa A., Motohashi S., Ishikawa E., Fuchida H., Higashino K., Otsuji M., et al. A phase I study of alpha-galactosylceramide (KRN7000)-pulsed dendritic cells in patients with advanced and recurrent non-small cell lung cancer. Clin Cancer Res 2005, 11:1910-1917.
13. Nieda M., Okai M., Tazbirkova A., Lin H., Yamaura A., Ide K., et al. Therapeutic activation of Valpha24+Vbeta11+NKT cells in human subjects results in highly coordinated secondary activation of acquired and innate immunity. Blood 2004, 103:383-389.
14. Knight A. Animal experiments scrutinised: systematic reviews demonstrate poor human clinical and toxicological utility. ALTEX 2007, 24:320-325.
15. Greek R., Menache A. Systematic reviews of animal models: methodology versus epistemology. Int J Med Sci 2013, 10:206-221.
16. Yin W., Carballo-Jane E., McLaren D.G., Mendoza V.H., Gagen K., Geoghagen N.S., et al. Plasma lipid profiling across species for the identification of optimal animal models of human dyslipidemia. J Lipid Res 2012, 53:51-65.
17. Freigang S., Kain L., Teyton L. Transport and uptake of immunogenic lipids. Mol Immunol 2013, 55:179-181.
18. Carnaud C., Lee D., Donnars O., Park S.H., Beavis A., Koezuka Y., et al. Cutting edge: cross-talk between cells of the innate immune system: NKT cells rapidly activate NK cells. J Immunol 1999, 163:4647-4650.
19. Freigang S., Zadorozhny V., McKinney M.K., Krebs P., Herro R., Pawlak J., et al. Fatty acid amide hydrolase shapes NKT cell responses by influencing the serum transport of lipid antigen in mice. J Clin Investig 2010, 120:1873-1884.
20. Thomas S.Y., Scanlon S.T., Griewank K.G., Constantinides M.G., Savage A.K., Barr K.A., et al. PLZF induces an intravascular surveillance program mediated by long-lived LFA-1-ICAM-1 interactions. J Exp Med 2011, 208:1179-1188.